JNJ vs ABT Stock Comparison

Johnson & Johnson and Abbott Laboratories Prices as of Nov 13, 2026 Peers: Industry group
JNJ Johnson & Johnson
$286.11 +12.7% 1M +46.5% 1Y
Market cap
$688.76B
P/E
42.8x
Revenue (TTM)
$99.34B
Div. yield
1.85%
Pharmaceuticals Healthcare
8 wins
ABT Abbott Laboratories
$108.54 +5.4% 1M -16.0% 1Y
Market cap
$187.98B
P/E
40.0x
Revenue (TTM)
$48.23B
Div. yield
2.32%
Medical Devices Healthcare
4 wins

Head to Head

12 decided of 12

Johnson & Johnson leads on 8 of the 12 questions below (Johnson & Johnson 8, Abbott Laboratories 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionJNJABTLeader
Larger companyMarket capitalisation $688.76B $187.98B JNJ
Cheaper on earningsLower P/E, profitable companies only 42.8x 40.0x ABT
Cheaper on forward earningsLower price / next fiscal year consensus EPS 26.7x 19.1x ABT
Faster revenue growthRevenue growth, trailing twelve months +7.8% +10.0% ABT
More profitableNet margin, trailing twelve months 16.2% 9.7% JNJ
Better return on capitalReturn on invested capital 17.6% 5.7% JNJ
Less leveragedLower net debt / EBITDA 0.8x 2.5x JNJ
Higher dividend yieldTrailing dividend yield 1.85% 2.32% ABT
Better 1-year returnPrice return, last 12 months +46.5% -16.0% JNJ
Better 5-year returnAnnualised price return, 5 years +11.6%/yr -3.3%/yr JNJ
Less volatileAnnualised volatility, 1 year 21.2% 28.5% JNJ
Higher overall scoreMean of the five percentile scores vs peers 65/100 56/100 JNJ

Percentile Scorecard

JNJABT

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisJNJABT
Valuation 84 #104 of 660 74 #65 of 243
Growth 34 #410 of 619 26 #168 of 228
Profitability 94 #39 of 595 82 #41 of 222
Financial Health 39 #416 of 683 33 #167 of 248
Shareholder Returns 73 #123 of 459 65 #56 of 158
Overall 65 56
  • JNJ ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ABT ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodJNJABTSPY
1 month +12.7%+5.4% -2.0%
3 months +9.9%-2.4% -2.8%
6 months +26.2%+28.5% +2.0%
Year to date +38.3%-13.4% +10.6%
1 year +46.5%-16.0% +12.2%
3 years +93.8%+11.8% +68.1%
3 years, per year +24.7%+3.8% +18.9%
5 years +73.4%-15.5% +61.4%
5 years, per year +11.6%-3.3% +10.1%
10 years +141.5%+170.4% +248.5%
10 years, per year +9.2%+10.5% +13.3%

Risk

MeasureJNJABTSPY
Volatility, 1Y 21.2%28.5% 13.6%
Downside volatility, 1Y 20.1%27.8% 13.9%
Beta vs S&P 500, 1Y -0.090.07 1.00
Return / volatility, 1Y 2.19-0.56 0.90
Max drawdown, 5Y -23.6%-41.6% -25.4%
From 52-week high 0.0%-16.9% -3.2%
52-week high $286.11$130.59 $779.14
52-week low $195.25$82.56 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleJNJABT
P/E now vs peer median 42.8xmedian 17.0x 40.0xmedian 26.5x
P/S now vs peer median 6.9xmedian 8.4x 3.9xmedian 2.7x
EV/EBITDA now vs peer median 21.5xmedian 14.6x 20.3xmedian 18.4x
P/FCF now vs peer median 33.5xmedian 19.0x 27.8xmedian 25.4x
P/B now vs peer median 8.4xmedian 2.0x 3.6xmedian 2.5x
PEG now vs peer median -1.42median 0.43 -13.92median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsJNJABT
Revenue $99.34B $48.23B
Gross profit $67.11B $27.46B
Operating income $25.19B $6.65B
Net income $16.10B $4.70B
Free cash flow $20.59B $6.76B
R&D $16.08B $3.31B
EPS (diluted) $6.57 $2.70
Cash & equivalents $16.91B $4.05B
Total debt $44.65B $31.16B
Shares (diluted) 2.45B 1.74B
Enterprise value $608.62B $162.45B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricJNJABT
P/E 42.8x 40.0x
P/FCF 33.5x 27.8x
P/Operating cash flow 26.3x 21.2x
P/S 6.9x 3.9x
P/B 8.4x 3.6x
P/Tangible book 19.7x 5.9x
EV/EBITDA 21.5x 20.3x
EV/EBIT 28.4x 32.3x
EV/Revenue 7.2x 4.5x
EV/FCF 34.8x 31.8x
EV/Operating cash flow 27.4x 24.3x
PEG (3Y EPS CAGR) -1.42 -13.92

Growth

14 metrics
MetricJNJABT
Revenue growth (1Y) 7.8% 10.0%
Revenue CAGR (3Y) -14.5% 6.5%
Gross profit growth (1Y) 7.0% 12.1%
Gross profit CAGR (3Y) -12.3% 7.8%
Operating income growth (1Y) 7.4% -13.8%
Operating income CAGR (3Y) -12.8% 3.5%
Net income growth (1Y) -35.9% -66.4%
Net income CAGR (3Y) -31.0% -3.1%
EPS growth (1Y) -36.4% -66.1%
EPS CAGR (3Y) -30.1% -2.9%
Operating cash flow growth (1Y) 8.1% -2.9%
Operating cash flow CAGR (3Y) 11.4% 10.6%
Free cash flow growth (1Y) 5.1% -2.3%
Free cash flow CAGR (3Y) 8.8% 14.6%

Profitability

14 metrics
MetricJNJABT
Gross margin 67.6% 56.9%
EBITDA margin 33.5% 21.9%
Operating margin 25.4% 13.8%
Pretax margin 17.9% 13.6%
Net margin 16.2% 9.7%
FCF margin 20.7% 14.0%
Operating cash flow margin 26.3% 18.4%
Return on equity 19.3% 9.1%
Return on assets 8.1% 4.3%
Return on invested capital 17.6% 5.7%
Return on capital employed 17.5% 7.2%
Asset turnover 0.5x 0.4x
Cash conversion (OCF / net income) 1.6x 1.9x
Stock comp / revenue 1.4% 1.5%

Financial Health

11 metrics
MetricJNJABT
Debt / assets 22.6% 28.8%
Debt / equity 0.5x 0.6x
Net debt / EBITDA 0.8x 2.5x
Debt / FCF 2.2x 4.6x
Liabilities / assets 58.7% 52.3%
Equity / assets 41.3% 47.7%
Interest coverage 25.6x 6.7x
Current ratio 1.0x 1.5x
Quick ratio 0.7x 0.8x
Cash ratio 0.3x 0.3x
Altman Z-score 5.69 3.36

Shareholder Returns

7 metrics
MetricJNJABT
Dividend yield 1.8% 2.3%
Net buyback yield 0.6% 0.7%
Shareholder yield 2.4% 3.0%
Payout ratio (earnings) 79.0% 92.0%
Payout ratio (FCF) 61.8% 64.0%
Dividend growth (1Y) 3.9% 6.9%
Dividend CAGR (3Y) 2.8% 7.4%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusJNJABT
Forward P/E 26.7xFY2026 19.1xFY2026
EPS, next fiscal year $10.72FY2026 $5.69FY2026
EPS growth, next FY -0.6%FY2026 +10.5%FY2026
EPS growth, the year after +5.8% +10.2%
Revenue, next fiscal year $106.55BFY2026 $52.99BFY2026
Revenue growth, next FY +13.1%FY2026 +19.5%FY2026
Revenue growth, the year after +6.8% -2.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersJNJABT
Held by institutions 74.7% 79.2%
Institutions holding 4,699 2,983
Change in shares held, QoQ +1.8% +0.3%
Institutions buying 2,297 1,261
Institutions selling 1,899 1,379
Buyers to sellers 1.21 0.91

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

JNJABT
JNJ 1.00 0.29
ABT 0.29 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, JNJ and ABT?

Johnson & Johnson (JNJ) is the largest by market capitalisation: Johnson & Johnson (JNJ) $688.76B, Abbott Laboratories (ABT) $187.98B.

Which stock is cheaper, JNJ and ABT?

Abbott Laboratories (ABT) trades on the lowest price-to-earnings ratio (Johnson & Johnson (JNJ) 42.8x, Abbott Laboratories (ABT) 40.0x). On next year's consensus earnings, Abbott Laboratories (ABT) is cheapest (Johnson & Johnson (JNJ) 26.7x, Abbott Laboratories (ABT) 19.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Abbott Laboratories (ABT) grew revenue fastest over the trailing twelve months: Johnson & Johnson (JNJ) +7.8%, Abbott Laboratories (ABT) +10.0%.

Which company is more profitable?

Johnson & Johnson (JNJ) has the highest net margin (Johnson & Johnson (JNJ) 16.2%, Abbott Laboratories (ABT) 9.7%). On return on invested capital, Johnson & Johnson (JNJ) leads (Johnson & Johnson (JNJ) 17.6%, Abbott Laboratories (ABT) 5.7%).

Which stock has performed better?

Over the past year Johnson & Johnson (JNJ) returned the most: Johnson & Johnson (JNJ) +46.5%, Abbott Laboratories (ABT) -16.0%. Over five years, Johnson & Johnson (JNJ) compounded fastest (Johnson & Johnson (JNJ) +11.6%/yr, Abbott Laboratories (ABT) -3.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Abbott Laboratories (ABT) has the highest dividend yield: Johnson & Johnson (JNJ) 1.85%, Abbott Laboratories (ABT) 2.32%.

Which stock is riskier?

By one-year price volatility, Johnson & Johnson (JNJ) has been the steadiest (Johnson & Johnson (JNJ) 21.2%, Abbott Laboratories (ABT) 28.5%). Volatility measures how widely the price swings, not the risk of the business.

Do JNJ and ABT move together?

Their daily returns over the past year have a correlation of 0.29, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, JNJ and ABT?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Johnson & Johnson (JNJ) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.